Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Imatinib mesylate
Drug ID BADD_D01137
Description Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
Indications and Usage For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
Marketing Status Prescription; Discontinued
ATC Code L01EA01
DrugBank ID DB00619
KEGG ID D01441
MeSH ID D000068877
PubChem ID 123596
TTD Drug ID D0AZ3C
NDC Product Code 55111-939; 64679-793; 72606-557; 63629-2067; 11722-052; 0904-6621; 60505-2901; 68382-244; 68382-245; 68001-490; 16714-705; 72485-203; 51991-376; 64679-794; 72485-202; 62068-309; 67877-634; 54893-0066; 63629-2068; 81955-0002; 72606-556; 62756-875; 68001-491; 47335-475; 70771-1394; 60505-2900; 0078-0401; 0904-6901; 60687-192; 42385-720; 0054-0249; 51991-377; 47335-472; 65344-0020; 0054-0248; 16714-704; 50268-426; 59651-240; 59651-241; 73309-059; 67877-633; 0093-7629; 42385-316; 0078-0649; 71052-670; 60687-203; 59923-723; 54893-0005; 59651-610; 0093-7630; 66499-0073; 70771-1395; 50268-427; 72969-033; 59923-724
Synonyms Imatinib Mesylate | Mesylate, Imatinib | Imatinib Methanesulfonate | Methanesulfonate, Imatinib | STI571 | STI-571 | STI 571 | Gleevec | Glivec | ST 1571 | ST1571 | CGP 57148 | CGP57148B | CGP-57148 | CGP57148 | Imatinib | Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
Chemical Information
Molecular Formula C30H35N7O4S
CAS Registry Number 220127-57-1
SMILES CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)( =O)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea02.01.03.002; 22.02.01.004--
Dyspnoea exertional02.01.03.003; 22.02.01.005--Not Available
Ecchymosis01.01.03.001; 23.06.01.001; 24.07.06.002--Not Available
Eosinophilia01.02.04.001--
Epistaxis22.04.03.001; 24.07.01.005--
Eructation07.01.02.003--
Erythema23.03.06.001--Not Available
Erythema multiforme10.01.03.015; 23.03.01.003--
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Eyelid oedema06.04.04.004; 10.01.05.001; 23.04.01.003--Not Available
Face oedema08.01.07.003; 10.01.05.002; 23.04.01.004--
Fatigue08.01.01.002--
Febrile neutropenia01.02.03.002; 08.05.02.004--
Flatulence07.01.04.002--
Fluid retention14.05.06.002; 20.01.02.003--Not Available
Flushing08.01.03.025; 23.06.05.003; 24.03.01.002--
Folliculitis11.01.12.018; 23.09.04.007--
Fungal infection11.03.05.001--Not Available
Gastric ulcer07.04.03.002--
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis07.19.03.001; 11.01.07.004--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.009--Not Available
Gastrointestinal perforation07.04.04.001--Not Available
Generalised oedema08.01.07.004; 14.05.06.007--
Glaucoma06.03.01.002--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 9 Pages